Zentiva NV develops, manufactures, and markets branded generic pharmaceutical products. The company provides generic drugs, cosmetics, and pharmaceutical substances. It offers products in various therapeutic areas, including cardiovascular diseases, disorders of central nervous system, digestion system, diabetes, inflammatory conditions, pain, infection, gastrointestinal, urinary tract and genital system, and treatment of respiratory diseases. In addition, the company provides dietary supplements and active pharmaceutical ingredients. Zentiva NV sells its pharmaceutical products in the Czech Republic, Turkey, Romania, Slovakia, Poland, and Russia, as well as in Ukraine, the Baltic States, Hu...
Fred Roeskestraat 123
Amsterdam, 1076 EE
Founded in 1998
31 20 673 9753
31 20 470 8362
Zentiva NV Announces Earnings Results for the First Half of 2014
Aug 12 14
Zentiva NV announced earnings results for the first half of 2014. For the period, the company reported net profit of RON 27.17 million compared with RON 28.35 million for the same period a year ago. Operating profit was RON 33.80 million compared with RON 33.50 million for the same period a year ago. Net turnover was RON 200.13 million compared with RON 160.86 million for the same period a year ago. Total revenue was RON 205.35 million compared with RON 162.05 million for the same period a year ago.
Zentiva Reports Earnings Results for the First Half of 2013
Aug 14 13
Zentiva reported earnings results for the first half of 2013. The company's net profit rose to RON 28.35 million ($8.5 million/€6.4 million) in the first half of 2013 from RON 21.24 million a year earlier. Operating profit was RON 33.50 million, compared to RON 24.66 million a year earlier. Net turnover was RON 160.86 million, compared to RON 139.37 million a year earlier. Total revenue was RON 162.05 million, compared to RON 153 million a year earlier.